Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey

• Published in: Digestive diseases (Basel) Vol. 35; no. 5; p. 423
• Main Authors: Vavricka, Stephan R, Spasojevic, Milos, Rogler, Gerhard, Schoepfer, Alain M, Seibold, Frank, Borovicka, Jan, Frei, Pascal, Zeitz, Jonas, Greuter, Thomas, Manser, Christine, Scharl, Michael, Misselwitz, Benjamin, Straumann, Alex, Michetti, Pierre, Biedermann, Luc
• Format: Journal Article
• Language: English
• Published: Switzerland 01.01.2017
• Subjects: Adult; Certolizumab Pegol - adverse effects; Certolizumab Pegol - therapeutic use; Cohort Studies; Crohn Disease - drug therapy; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle Aged; Registries; Surveys and Questionnaires; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Anti-tumor necrosis factor; Real-life cohort; Long-term efficacy; Certolizumab; Crohn’s disease

Long-term data of certolizumab pegol (CZP) in Crohn's disease (CD) from pivotal registry trials are limited. We therefore aimed to evaluate the long-term efficacy of CZP in clinical practice in Switzerland. In the First Approved Certolizumab Therapeutic Experience in Switzerland-III phase IV mu...